Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Over 1,800 people in Montana had to be hospitalized with either influenza or COVID-19 during the last respiratory illness ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Health experts say there are plenty of ways to halt the spread of respiratory illnesses as Michigan's weather grows colder.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

They are respiratory infections that cause similar symptoms such as coughing, fever and fatigue. These illnesses can range ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

A mother whose newborn son almost died after contracting a respiratory virus is warning others not to its "underestimate" symptoms. Just two weeks after Gemma gave birth to her son Harry in December ...